A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction
- PMID: 38963839
- DOI: 10.1126/science.adk6129
A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction
Abstract
Sickle cell disease (SCD) is a prevalent, life-threatening condition attributable to a heritable mutation in β-hemoglobin. Therapeutic induction of fetal hemoglobin (HbF) can ameliorate disease complications and has been intently pursued. However, safe and effective small-molecule inducers of HbF remain elusive. We report the discovery of dWIZ-1 and dWIZ-2, molecular glue degraders of the WIZ transcription factor that robustly induce HbF in erythroblasts. Phenotypic screening of a cereblon (CRBN)-biased chemical library revealed WIZ as a previously unknown repressor of HbF. WIZ degradation is mediated by recruitment of WIZ(ZF7) to CRBN by dWIZ-1, as resolved by crystallography of the ternary complex. Pharmacological degradation of WIZ was well tolerated and induced HbF in humanized mice and cynomolgus monkeys. These findings establish WIZ degradation as a globally accessible therapeutic strategy for SCD.
Comment in
-
Developing a pill to treat sickle cell disease.Science. 2024 Jul 5;385(6704):27-28. doi: 10.1126/science.adq3757. Epub 2024 Jul 4. Science. 2024. PMID: 38963861
-
Molecular glue degrader for sickle cell disease.Nat Rev Drug Discov. 2024 Sep;23(9):659. doi: 10.1038/d41573-024-00122-3. Nat Rev Drug Discov. 2024. PMID: 39043933 No abstract available.
Similar articles
-
Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell Disease.J Med Chem. 2024 Nov 28;67(22):20682-20694. doi: 10.1021/acs.jmedchem.4c02251. Epub 2024 Nov 14. J Med Chem. 2024. PMID: 39541509
-
Discovery of a novel molecular glue degrader targeting GSPT1/2 with a non-IMiD-based CRBN binder.Eur J Med Chem. 2025 Jul 5;291:117642. doi: 10.1016/j.ejmech.2025.117642. Epub 2025 Apr 15. Eur J Med Chem. 2025. PMID: 40252382
-
Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.Eur J Med Chem. 2021 Jan 1;209:112938. doi: 10.1016/j.ejmech.2020.112938. Epub 2020 Oct 16. Eur J Med Chem. 2021. PMID: 33109398
-
Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.Cell Chem Biol. 2021 Jul 15;28(7):987-999. doi: 10.1016/j.chembiol.2021.04.012. Epub 2021 May 24. Cell Chem Biol. 2021. PMID: 34033753 Review.
-
Fetal haemoglobin induction in sickle cell disease.Br J Haematol. 2018 Jan;180(2):189-200. doi: 10.1111/bjh.15021. Epub 2017 Nov 16. Br J Haematol. 2018. PMID: 29143315 Free PMC article. Review.
Cited by
-
Molecular glue degrader for sickle cell disease.Nat Rev Drug Discov. 2024 Sep;23(9):659. doi: 10.1038/d41573-024-00122-3. Nat Rev Drug Discov. 2024. PMID: 39043933 No abstract available.
-
Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease.Int J Mol Sci. 2024 Nov 5;25(22):11886. doi: 10.3390/ijms252211886. Int J Mol Sci. 2024. PMID: 39595957 Free PMC article. Review.
-
Toward life without sickle cell disease.Mol Ther. 2024 Oct 2;32(10):3197-3198. doi: 10.1016/j.ymthe.2024.09.004. Epub 2024 Sep 17. Mol Ther. 2024. PMID: 39293432 No abstract available.
-
Target agnostic cellular screening in the era of chemically induced proximity.RSC Med Chem. 2025 Jul 21. doi: 10.1039/d5md00529a. Online ahead of print. RSC Med Chem. 2025. PMID: 40756522 Free PMC article. Review.
-
Targeted protein degradation for cancer therapy.Nat Rev Cancer. 2025 Jul;25(7):493-516. doi: 10.1038/s41568-025-00817-8. Epub 2025 Apr 25. Nat Rev Cancer. 2025. PMID: 40281114 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases